US DFC announced $765 million loan to Eastman Kodak to support new expansion into pharmaceuticals
On Jul. 28, 2020, the U.S. International Development Finance Corp. (DFC) announced that it had signed a letter…
Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
ViralClear partnered with Albany Molecular on manufacture of merimepodib API development for potential treatment of COVID-19
On Jul. 9, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that it is partnering with Albany…
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
Fujifilm partnered with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan
On Jul. 1, 2020, FUJIFILM announced a partnership with Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in…
Takeda received FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at Brooklyn Park, Minnesota facility
On Jun. 23, 2020, Takeda Pharmaceutical announced that the FDA had approved the company’s submission for its biologics…
Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
On Jun. 22, 2020, Catalent announced that it had signed an agreement with ViralClear Pharmaceuticals, a subsidiary of…
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo (nivolumab) was approved by the FDA for the treatment…
Johnson & Johnson received positive CHMP opinion for Janssen’s investigational preventive Ebola vaccine regimen
On May 29, 2020, Johnson & Johnson announced that its Janssen Pharmaceutical subsidiary received a positive opinion from…
Sanofi announced pricing of Regeneron stock offering
On May 26, 2020, Sanofi announced that it had agreed to sell 11.8 million shares of Regeneron common…
The CoVIg-19 Plasma Alliance was established
On May 8, 2020, the CoVIg-19 Plasma Alliance was announced, an unprecedented partnership of the world’s leading plasma…
AbbVie completed acquisition of Allergan for nearly $62 billion
On May 8, 2020, AbbVie announced it had completed its acquisition of Allergan following receipt of regulatory approval…
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with PrecisionNanoSystems (PNI) to produce clinica lgrade vaccines and…
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase…
Laurent Pharmaceuticals received Health Canada’s approval to initiate COVID-19 clinical trial
On May 6, 2020, Laurent Pharmaceuticals announced that it has obtained the approval from Health Canada to initiate…
Biotechnology | COVID-19 | Diagnostics | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
Entos Pharmaceuticals partnered with EpiVax to develop a pan-Coronavirus DNA vaccine
On Apr. 28, 2020, Entos Pharmaceuticals announced a collaboration with EpiVax. This partnership combined the Entos Fusogenix DNA…
Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…
Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…
Emergent BioSolutions signed agreement to be U.S. manufacturing partner for Johnson & Johnson’s lead vaccine candidate for COVID-19
On Apr. 23, 2020, Emergent BioSolutions announced an agreement whereby Emergent will deploy its contract development and manufacturing…
Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…
ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials
On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib,…
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
Amneal Pharmaceuticals donated hydroxychloroquine sulfate to state of Texas
On Mar. 26, 2020, Amneal Pharma announced it had donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State…
Innovation Pharmaceuticals Brilacidin tested as drug and vaccine at different institutions
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
Enanta Pharmaceuticals announced efforts to discover treatment for novel Coronavirus disease
On Mar. 13, 2020, Enanta Pharmaceuticals announced it had initiated a program to discover direct-acting antiviral drug candidates…
FDA approved Lundbeck’s VYEPTI™ – the first and only intravenous preventive treatment for migraine
On Feb. 21, 2020, Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) had been approved by the U.S. Food and Drug…
BioMotiv and Bristol-Myers Squibb announced the Launch of Anteros Pharmaceuticals
On Feb. 4, 2020, BioMotiv and Bristol-Myers Squibb announced the launch of Anteros Pharmaceuticals, a biotechnology company focused…
Alexion completed acquisition of Achillion for $930 million
On Jan. 28, 2020, Alexion Pharma announced it had completed its acquisition of Achillion Pharmaceuticals for $930 million….